EchoStar Corporation Common Stock vs TG Therapeutics Inc — how do they compare? EchoStar Corporation Common Stock trades at $95.25 (market cap $28.41B), while TG Therapeutics Inc trades at $53.34 (market cap $8.11B). The key difference: EchoStar Corporation Common Stock is far larger — about 3.5× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, EchoStar Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 0 Days and TG Therapeutics Inc for 15 Days on average.
| ECHO | TGTX | |
|---|---|---|
Market Cap | $28.41B | $8.11B |
Volume | 3,258,295 | 1,505,658 |
Sector | Media | Health |
52-Week High | $141.80 | $59.06 |
52-Week Low | $66.93 | $26.94 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $45.47B | $8.31B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →